Artwork

Conteúdo fornecido por Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

37. Injectable Vs. Sublingual Buprenorphine

46:46
 
Compartilhar
 

Manage episode 399348333 series 3378548
Conteúdo fornecido por Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

37. Injectable Vs. Sublingual Buprenorphine

In episode 37 we discuss an article comparing injectable and sublingual buprenorphine.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine, Volume 66, 102311

We also discuss new data on the teratogenicity of fentanyl, and a new genetic test to identify the risk for opioid use disorder.

Genetics on Medicine Open: A novel syndrome associated with prenatal fentanyl exposure

FDA: FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder

----------

This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES.

----------

Episode 37 Credits:

----------

This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.

The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.

Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

  continue reading

57 episódios

Artwork
iconCompartilhar
 
Manage episode 399348333 series 3378548
Conteúdo fornecido por Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

37. Injectable Vs. Sublingual Buprenorphine

In episode 37 we discuss an article comparing injectable and sublingual buprenorphine.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine, Volume 66, 102311

We also discuss new data on the teratogenicity of fentanyl, and a new genetic test to identify the risk for opioid use disorder.

Genetics on Medicine Open: A novel syndrome associated with prenatal fentanyl exposure

FDA: FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder

----------

This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES.

----------

Episode 37 Credits:

----------

This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.

The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.

Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

  continue reading

57 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências